XerostomiaNCT04738227
Effect of Low-level Laser Therapy on Salivary Flow, pH and Quality of Life in Irradiated Oropharyngeal Cancer Patients
A study testing Low-Level Laser Therapy in people with Xerostomia, run by Ziauddin University at 1 site in Pakistan.
Trial summary
There are multiple treatment modalities for head and neck cancer. They include radiation therapy, chemotherapy and surgery. Radiation therapy aims to control the tumor with minimum damage to adjacent tissues. Surgery is the preferred treatment for accessible cancers. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Xerostomia
- What is being tested?
- Low-Level Laser Therapy
- Type of treatment
- Surgery or procedure
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 34 participants
- Where
- 1 sitePakistan
- Study dates
- 6 Nov 2020to 3 Feb 2021
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Patients with radiation induced persistent xerostomia which will be confirmed clinically and by taking salivary flow rate. Patients which will have salivary flow rate less than 0.1-0.2 ml/min shall be included.
- Patients treated with therapeutic RT for oropharyngeal cancers 3 to 36 months ago
- Patients whose age was equal to or more than 18 years irrespective of gender.
Who cannot join
- Patients with other determined causes of xerostomia which have been confirmed. Systemic conditions (specially checking and excluding patients having dehydration,patients with known diseases of salivary glands, salivary glands removal surgery, smoking, diabetes, and autoimmune disorders among such as Sjögren's syndrome and drugs that cause xerostomia.
Trial locations and contacts
1 site in 1 country.
About this study
Official title: Effect of Low-level Laser Therapy on Salivary Flow, pH and Quality of Life in Irradiated Oropharyngeal Cancer Patients.
There are multiple treatment modalities for head and neck cancer. They include radiation therapy, chemotherapy and surgery. Radiation therapy aims to control the tumor with minimum damage to adjacent tissues. Surgery is the preferred treatment for accessible cancers. Radiation and/or chemotherapy is used as an adjunct to surgery, in inaccessible tumors, post surgery sterilization and palliation.
A major complication of RT is that adjacent normal tissues are variably affected.
Read more
For Oropharyngeal cancer, major and minor salivary glands are damaged by RT since they fall in the radiation pathway. Atrophy and acinar degeneration are features most commonly found histologically.
Xerostomia is defined as dry mouth resulting from reduced or absent saliva flow.
Xerostomia is not a disease, but may be a symptom of various medical conditions, a side effect of a wide variety of medications and a side effect of a radiation to the head and neck.The flow rate of normal unstimulated saliva is 0.3-0.5 ml/min. If it decreases to less than 0.1-0.2 ml/min, one would experience xerostomia.
According to researchers, the decrease in saliva and xerostomia that results from radiotherapy plays an important role in worsening Quality of Life(QoL) among patients who undergo radiotherapy for head and neck cancers.
Low level laser Therapy(LLLT) uses light energy in the form of photons to produce cellular responses in the cell. Light photons are absorbed by cytochromes and porphyrins in the mitochondria of the cell.
This study aims to prove that Low level laser therapy will improve salivary flow rate, pH and the quality of life in patients who have undergone Radiation therapy for oropharyngeal cancers.
Read the detailed description
There are multiple treatment modalities the cancers of the head and neck. The main three major treatment options are surgery, radiation therapy and chemotherapy. Radiation therapy (RT) is used to control the growth of the tumor with limiting the damage to adjacent tissues. Surgery is the main treatment for oropharyngeal cancers, but if the cancer remains, radiation and chemotherapy is used in adjunct to surgery. Radiation therapy is a common treatment options for initial to mid stage malignancies.
A major complication of RT is that non neoplastic tissues of the head and neck are variably affected. The exact amount of damage to healthy tissues depends on factors such as fraction of radiation dose, the total amount of the radiation dose administered, volume of irradiated tissue, and how the dose is distributed in the tissue. The effect on the tissues may appear either during the treatment (acute) or once the treatment is complete (late).
For Oropharyngeal cancer, major and minor salivary glands are mostly affected by RT due to the fact that salivary glands fall in the radiation pathway. The mechanisms by which the tissues and cells are damaged due to radiation are still not very clear, but the features most commonly found histologically are atrophy of the tissues and degeneration of the acini. According to researchers, "the decrease in saliva and xerostomia that results from radiotherapy plays an important role in worsening Quality of Life (QoL) among patients who undergo radiotherapy for head and neck cancers". The normal flow rate of unstimulated saliva is 0.3-0.5 ml/min. If it decreases to less than 0.1-0.2 ml/min, it is then that one would experience xerostomia Xerostomia Inventory (XI) which was formulated by Thomson is a validated tool which will also be used to determine the amount of dryness based on the XI score. A higher score will be suggestive of worsening xerostomia.
The most commonly recommended treatment for xerostomia currently is intraoral topical agents. These include salivary stimulants, chewing gums, topical sprays containing malic acid. Also used for xerostomia are medicines such has pilocarpine and cevimeline but both medicines are parasympathomimetic and need to be administered with extreme caution. The effectiveness of there medicines is short lived and only provide symptomatic relief.
Generally, the mechanism by which Low level laser Therapy(LLLT) works is that photons are generated through the light energy and these photons produce cellular responses in the cell. The photons of light are readily absorbed by the cytochromes and the porphyrins present in the mitochondria of the cell.
Low level laser therapy has many diverse effects on the tissues and cells of the body. Previous experimental animal studies highlight a positive effect on the salivary glands when low level laser therapy was applied. Mitotic activity was seen to be stimulated by LLLT to quite an extent in the epithelial tissue of salivary glands of murine test subjects. As a result, the salivary flow rate (SFR) increased, the enzymatic activity increased in saliva significantly as there was a decrease in the activity of peroxidase and catalase enzymes and it was shown to alter the protein concentration in saliva [14,15]. Once the cells receive the LLLT, are more acidic because of the lowered redox state, but soon after the laser therapy they become alkaline resulting in optimal function. Healthy cells are not affected by LLLT as it does not increase their redox potential.
One of the most common side effect of radiation therapy for the oropharyngeal region is Xerostomia. Xerostomia leads to a significant decrease in oral health causing mucositis, dental caries, oral ulcers, periodontal infections etc. These symptoms result in a decrease in the QoL of the patients treated with radiation therapy for oropharyngeal cancers. The conventional treatment for xerostomia is short term symptomatic relief. There is an utmost need for long term treatment that saves the patients from relying on short term treatments.
Objective To determine the effect of low level laser therapy on saliva flow rate in patients who have undergone Radiation therapy for oropharyngeal cancers.
To determine the effect of low level laser therapy on pH of saliva produced in patients who have undergone Radiation therapy for oropharyngeal cancers.
To determine the effect of low level laser therapy on Quality of Life (QoL) in patients who have undergone Radiation therapy for oropharyngeal cancers.
Rationale of the Study Previous studies used a higher wavelength diode laser (808 and 980nm) with controversial results. Some showed excellent results whereas some showed no results at all. The rationale behind choosing a lower wavelength (635nm) in our study is the potentially higher beneficial absorption, to functionally stimulate the damaged, residual salivary glands. No study has been conducted on this particular topic in the Indo-Pak region. Hence, effects of LLLT on salivary glands need to be evaluated.
Significance of the Study As head and neck cancers are increasing in Pakistan, the role of radiation therapy has increased. The side effects of radiation to healthy tissues such as the salivary glands causes severe impairment of oral health and overall quality of life. Low level laser therapy is a relatively non-invasive, cost effective and a new method for treating patients with xerostomia due to radiation therapy. By stimulating residual salivary tissue it may provide long term or permanent (as against symptomatic) relief.
The research would be will be conducted in Karachi, Pakistan where all the facilities of the Laser are available. The procedure will also be done under the supervision of my clinical supervisor, who is a Laser Safety Officer authorized to conduct laser procedures. The patients will be recruited from Ziauddin Hospital where the patients were successfully treated with radiotherapy for oropharyngeal cancers.
Target population The target population will be patients treated with radiotherapy for oropharyngeal cancer in Karachi, Pakistan
Duration of study The duration of study will be 1 year from the date of approval from the Board of advanced studies and research.
The experimental time period will be 12 weeks in which the Patients will be given LLLT two times a week. Each patient would be called at 9am in the morning each day and each patient will have their schedule through out the week so overlapping can be minimized.
Procedure Laser therapy will be performed with a continuous wave diode laser device previously calibrated by the manufacturer.
6 points that will be the skin overlying the right hand side parotid gland and 3 points on the skin overlying the location of the right hand side submandibular gland).
Following are the parameters which will be employed for the laser:
Wavelength - 635nm (visible spectrum), Output power 100 milliwatt, Mean dose per point - 18.75 J/cm2 , Irradiation time per point 15 s Energy per point 3 J Energy per session 33 J , Laser spot tip will be 0.08cm2 Two laser sessions will be done each week, during 12 weeks, which will bring the total number of laser sessions to All the major salivary glands will be treated with the tip of the laser hand-piece in contact with patients tissues.
A sum total of 22 points will receive LLLT per session involving all three major salivary glands.
Parameters to be assessed Three parameters will be assessed
- Stimulated and Unstimulated salivary flow
- pH
- Quality of Life using University of Washington Quality of Life questionnaire
- Conditions
- Xerostomia
- Being tested
- Low-Level Laser Therapy
- Medical subject headings
- Xerostomia
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Low-Level Laser TherapyRadiation
Low level laser will be applied and post laser results will be seen to assess any improvements.
| Study group | Role | What they receive |
|---|---|---|
| Low level Laser Therapy Group | Experimental | Laser therapy will be performed with a continuous wave diode laser device previously calibrated by the manufacturer.
6 points that will be the skin overlying the right hand side parotid gland and 3 points on the skin overlying the location of the right hand side submandibular gland).
Following are the parameters which will be employed for the laser:
Wavelength - 635nm (visible spectrum), Output power 100 milliwatt, Mean dose per point - 3 J/cm2 , Irradiation time per point 15 s Energy per point 3 J Energy per session 60 J , Laser spot tip will be 0.08cm2 Two laser sessions will be done each week, during 12 weeks, which will bring the total number of laser sessions to All the major salivary glands will be treated with the tip of the laser hand-piece in contact with patients tissues.
A sum total of 22 points will receive LLLT per session involving all three major salivary glands. Receives: Radiation: Low-Level Laser Therapy |
What is being measured
The primary outcome is the main question the study is designed to answer.
Increase in Salivary flow rate
Increase in salivary flow rate in patients who have undergone Radiation therapy for oropharyngeal cancers.
Measured: 12 weeks
Increase in pH
Increase in pH in patients who have undergone Radiation therapy for oropharyngeal cancers.
Measured: 12 weeks
Increase in Quality of Life questionnaire Score
Increase in the quality of life in patients who have undergone Radiation therapy for oropharyngeal cancers.
The questionnaire has 13 close ended questions. The total score of the questionnaire will be between 0-1300 A higher score will indicate improvement in the quality of life and will be compared with the score taken at baseline, before the start of the study.
Measured: 12 weeks
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted4 Feb 2021
- Study start6 Nov 2020
- Primary completion3 Feb 2021
- Study completion3 Feb 2021
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for XerostomiaStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Supportive care
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Enrolment
- 34 participants (actual)
Sponsor and investigators
- Lead sponsor
- Ziauddin University
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Dr. Danial Arshad, Ziauddin University
- Investigators
- Danial Arshad, M.Phil, Principal investigator, Ziauddin University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT04738227
- Sponsor's protocol ID
- 2480820DAOM
- Status last verified
- Jul 2021
- First submitted
- 1 Feb 2021
- Last updated
- 30 Jul 2021
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 30 Jul 2021. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Effect of Low-level Laser Therapy on Salivary Flow, pH and Quality of Life in Irradiated Oropharyngeal Cancer Patients.
- ClinicalTrials.gov ID
- NCT04738227
- Acronym / sponsor ID
- 2480820DAOM
- Conditions
- Xerostomia
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 34 participants (actual)
- Lead sponsor
- Ziauddin UniversityUniversity, hospital or other
- Study start
- 6 Nov 2020 (actual)
- Primary completion
- 3 Feb 2021 (actual)
- Study completion
- 3 Feb 2021 (actual)
- First posted
- 4 Feb 2021 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
There are multiple treatment modalities for head and neck cancer. They include radiation therapy, chemotherapy and surgery. Radiation therapy aims to control the tumor with minimum damage to adjacent tissues. Surgery is the preferred treatment for accessible cancers. Radiation and/or chemotherapy is used as an adjunct to surgery, in inaccessible tumors, post surgery sterilization and palliation.
A major complication of RT is that adjacent normal tissues are variably affected.
For Oropharyngeal cancer, major and minor salivary glands are damaged by RT since they fall in the radiation pathway. Atrophy and acinar degeneration are features most commonly found histologically.
Xerostomia is defined as dry mouth resulting from reduced or absent saliva flow.
Xerostomia is not a disease, but may be a symptom of various medical conditions, a side effect of a wide variety of medications and a side effect of a radiation to the head and neck.The flow rate of normal unstimulated saliva is 0.3-0.5 ml/min. If it decreases to less than 0.1-0.2 ml/min, one would experience xerostomia.
According to researchers, the decrease in saliva and xerostomia that results from radiotherapy plays an important role in worsening Quality of Life(QoL) among patients who undergo radiotherapy for head and neck cancers.
Low level laser Therapy(LLLT) uses light energy in the form of photons to produce cellular responses in the cell. Light photons are absorbed by cytochromes and porphyrins in the mitochondria of the cell.
This study aims to prove that Low level laser therapy will improve salivary flow rate, pH and the quality of life in patients who have undergone Radiation therapy for oropharyngeal cancers.
Detailed description
There are multiple treatment modalities the cancers of the head and neck. The main three major treatment options are surgery, radiation therapy and chemotherapy. Radiation therapy (RT) is used to control the growth of the tumor with limiting the damage to adjacent tissues. Surgery is the main treatment for oropharyngeal cancers, but if the cancer remains, radiation and chemotherapy is used in adjunct to surgery. Radiation therapy is a common treatment options for initial to mid stage malignancies.
A major complication of RT is that non neoplastic tissues of the head and neck are variably affected. The exact amount of damage to healthy tissues depends on factors such as fraction of radiation dose, the total amount of the radiation dose administered, volume of irradiated tissue, and how the dose is distributed in the tissue. The effect on the tissues may appear either during the treatment (acute) or once the treatment is complete (late).
For Oropharyngeal cancer, major and minor salivary glands are mostly affected by RT due to the fact that salivary glands fall in the radiation pathway. The mechanisms by which the tissues and cells are damaged due to radiation are still not very clear, but the features most commonly found histologically are atrophy of the tissues and degeneration of the acini. According to researchers, "the decrease in saliva and xerostomia that results from radiotherapy plays an important role in worsening Quality of Life (QoL) among patients who undergo radiotherapy for head and neck cancers". The normal flow rate of unstimulated saliva is 0.3-0.5 ml/min. If it decreases to less than 0.1-0.2 ml/min, it is then that one would experience xerostomia Xerostomia Inventory (XI) which was formulated by Thomson is a validated tool which will also be used to determine the amount of dryness based on the XI score. A higher score will be suggestive of worsening xerostomia.
The most commonly recommended treatment for xerostomia currently is intraoral topical agents. These include salivary stimulants, chewing gums, topical sprays containing malic acid. Also used for xerostomia are medicines such has pilocarpine and cevimeline but both medicines are parasympathomimetic and need to be administered with extreme caution. The effectiveness of there medicines is short lived and only provide symptomatic relief.
Generally, the mechanism by which Low level laser Therapy(LLLT) works is that photons are generated through the light energy and these photons produce cellular responses in the cell. The photons of light are readily absorbed by the cytochromes and the porphyrins present in the mitochondria of the cell.
Low level laser therapy has many diverse effects on the tissues and cells of the body. Previous experimental animal studies highlight a positive effect on the salivary glands when low level laser therapy was applied. Mitotic activity was seen to be stimulated by LLLT to quite an extent in the epithelial tissue of salivary glands of murine test subjects. As a result, the salivary flow rate (SFR) increased, the enzymatic activity increased in saliva significantly as there was a decrease in the activity of peroxidase and catalase enzymes and it was shown to alter the protein concentration in saliva [14,15]. Once the cells receive the LLLT, are more acidic because of the lowered redox state, but soon after the laser therapy they become alkaline resulting in optimal function. Healthy cells are not affected by LLLT as it does not increase their redox potential.
One of the most common side effect of radiation therapy for the oropharyngeal region is Xerostomia. Xerostomia leads to a significant decrease in oral health causing mucositis, dental caries, oral ulcers, periodontal infections etc. These symptoms result in a decrease in the QoL of the patients treated with radiation therapy for oropharyngeal cancers. The conventional treatment for xerostomia is short term symptomatic relief. There is an utmost need for long term treatment that saves the patients from relying on short term treatments.
Objective To determine the effect of low level laser therapy on saliva flow rate in patients who have undergone Radiation therapy for oropharyngeal cancers.
To determine the effect of low level laser therapy on pH of saliva produced in patients who have undergone Radiation therapy for oropharyngeal cancers.
To determine the effect of low level laser therapy on Quality of Life (QoL) in patients who have undergone Radiation therapy for oropharyngeal cancers.
Rationale of the Study Previous studies used a higher wavelength diode laser (808 and 980nm) with controversial results. Some showed excellent results whereas some showed no results at all. The rationale behind choosing a lower wavelength (635nm) in our study is the potentially higher beneficial absorption, to functionally stimulate the damaged, residual salivary glands. No study has been conducted on this particular topic in the Indo-Pak region. Hence, effects of LLLT on salivary glands need to be evaluated.
Significance of the Study As head and neck cancers are increasing in Pakistan, the role of radiation therapy has increased. The side effects of radiation to healthy tissues such as the salivary glands causes severe impairment of oral health and overall quality of life. Low level laser therapy is a relatively non-invasive, cost effective and a new method for treating patients with xerostomia due to radiation therapy. By stimulating residual salivary tissue it may provide long term or permanent (as against symptomatic) relief.
The research would be will be conducted in Karachi, Pakistan where all the facilities of the Laser are available. The procedure will also be done under the supervision of my clinical supervisor, who is a Laser Safety Officer authorized to conduct laser procedures. The patients will be recruited from Ziauddin Hospital where the patients were successfully treated with radiotherapy for oropharyngeal cancers.
Target population The target population will be patients treated with radiotherapy for oropharyngeal cancer in Karachi, Pakistan
Duration of study The duration of study will be 1 year from the date of approval from the Board of advanced studies and research.
The experimental time period will be 12 weeks in which the Patients will be given LLLT two times a week. Each patient would be called at 9am in the morning each day and each patient will have their schedule through out the week so overlapping can be minimized.
Procedure Laser therapy will be performed with a continuous wave diode laser device previously calibrated by the manufacturer.
6 points that will be the skin overlying the right hand side parotid gland and 3 points on the skin overlying the location of the right hand side submandibular gland).
Following are the parameters which will be employed for the laser:
Wavelength - 635nm (visible spectrum), Output power 100 milliwatt, Mean dose per point - 18.75 J/cm2 , Irradiation time per point 15 s Energy per point 3 J Energy per session 33 J , Laser spot tip will be 0.08cm2 Two laser sessions will be done each week, during 12 weeks, which will bring the total number of laser sessions to All the major salivary glands will be treated with the tip of the laser hand-piece in contact with patients tissues.
A sum total of 22 points will receive LLLT per session involving all three major salivary glands.
Parameters to be assessed Three parameters will be assessed
- Stimulated and Unstimulated salivary flow
- pH
- Quality of Life using University of Washington Quality of Life questionnaire
Study design
- Primary purpose
- Supportive care
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Low level Laser Therapy Group | Experimental | Radiation: Low-Level Laser TherapyLaser therapy will be performed with a continuous wave diode laser device previously calibrated by the manufacturer. 6 points that will be the skin overlying the right hand side parotid gland and 3 points on the skin overlying the location of the right hand side submandibular gland). Following are the parameters which will be employed for the laser: Wavelength - 635nm (visible spectrum), Output power 100 milliwatt, Mean dose per point - 3 J/cm2 , Irradiation time per point 15 s Energy per point 3 J Energy per session 60 J , Laser spot tip will be 0.08cm2 Two laser sessions will be done each week, during 12 weeks, which will bring the total number of laser sessions to All the major salivary glands will be treated with the tip of the laser hand-piece in contact with patients tissues. A sum total of 22 points will receive LLLT per session involving all three major salivary glands. |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (3 listed)
- Patients with radiation induced persistent xerostomia which will be confirmed clinically and by taking salivary flow rate. Patients which will have salivary flow rate less than 0.1-0.2 ml/min shall be included.
- Patients treated with therapeutic RT for oropharyngeal cancers 3 to 36 months ago
- Patients whose age was equal to or more than 18 years irrespective of gender.
Key exclusion criteria (1 listed)
- Patients with other determined causes of xerostomia which have been confirmed. Systemic conditions (specially checking and excluding patients having dehydration,patients with known diseases of salivary glands, salivary glands removal surgery, smoking, diabetes, and autoimmune disorders among such as Sjögren's syndrome and drugs that cause xerostomia.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Low-Level Laser TherapyLow level laser will be applied and post laser results will be seen to assess any improvements. | Radiation | Low level Laser Therapy Group |
Primary outcome
Increase in Salivary flow rate
Time frame: 12 weeks
Increase in salivary flow rate in patients who have undergone Radiation therapy for oropharyngeal cancers.
Increase in pH
Time frame: 12 weeks
Increase in pH in patients who have undergone Radiation therapy for oropharyngeal cancers.
Increase in Quality of Life questionnaire Score
Time frame: 12 weeks
Increase in the quality of life in patients who have undergone Radiation therapy for oropharyngeal cancers. The questionnaire has 13 close ended questions. The total score of the questionnaire will be between 0-1300 A higher score will indicate improvement in the quality of life and will be compared with the score taken at baseline, before the start of the study.
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 30 Jul 2021.
- Individual participant dataSharing planned: No
Related trials for Xerostomia
RecruitingPhase 2
Safety of Tofacitinib, an Oral Janus Kinase Inhibitor, in Primary Sjogren Disease
Sjogren's Syndrome
RecruitingPhase 1/2
Study of Circular RNA Treatment in Patients With Radiation Induced Xerostomia-1
Radiation-Induced Xerostomia and Hyposalivation
RecruitingObservational study
Characterization of Diseases With Salivary Gland Involvement
Healthy Volunteer, Sjogren's Syndrome
Recruiting
Oral Health Intervention in Adult Primary Care
Dental Caries, Dry Mouth
Not yet recruiting
Oral Care Program for Mouth Side Effects During Head and Neck Radiation Therapy
Head and Neck Cancer (H&N), Oral Mucositis (Ulcerative) Due to Radiation
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Danial Arshad, M.Phil principal investigator
Ziauddin University
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Low-Level Laser Therapy in people with Xerostomia, run by Ziauddin University at 1 site in Pakistan.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 30 Jul 2021. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Pakistan. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Increase in Salivary flow rate (time frame: 12 weeks). The study lists 3 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 30 Jul 2021; AzTrials last refreshed its copy on 6 Nov 2026.